Not applicableActive Not RecruitingNCT07704801What this trial is testingCDK4/6 Inhibitors in Metastatic HR-Positive Breast CancerWho this might be right forMetastatic Breast Cancer Sohag University 300
Not applicableStudy completedNCT04498481What this trial is testingTREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.Who this might be right forBreast Cancer Pfizer 1
Not applicableUnknownNCT05167643What this trial is testingH (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyWho this might be right forAdvanced HR+ HER2 Negative Breast Carcinoma Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117What this trial is testingEvaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Who this might be right forLocally Advanced or Metastatic Malignant Solid Tumors Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)Looking for participantsNCT06486883What this trial is testingSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeWho this might be right forAdvanced Breast CancerAdvanced Breast CarcinomaHormone Receptor Positive Breast Carcinoma MedSIR 200
Testing effectiveness (Phase 2)Looking for participantsNCT05306041What this trial is testingNeoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerWho this might be right forHER2-positive Breast Cancer GBG Forschungs GmbH 170
Testing effectiveness (Phase 2)UnknownNCT05512780What this trial is testingDalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerWho this might be right forSolid Tumor Hebei Medical University Fourth Hospital 30
Not applicableUnknownNCT06174259What this trial is testingInfluence of Intermittent Fasting on Locally Advanced Breast Cancer PatientsWho this might be right forLocally Advanced Breast CancerIntermittent Fasting Menoufia University 66
Testing effectiveness (Phase 2)UnknownNCT03906669What this trial is testingA Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.Who this might be right forEarly-stage Breast CancerHormone Receptor Positive Tumor St Vincent's Hospital 200
Not applicableLooking for participantsNCT06930859What this trial is testingNon-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaWho this might be right forBreast Cancer Novartis Pharmaceuticals 2,766
Testing effectiveness (Phase 2)Looking for participantsNCT07195227What this trial is testingEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerWho this might be right forHormon Receptor Positive Breast CancerBreast Cancer MedSIR 150
Testing effectiveness (Phase 2)Study completedNCT03007992What this trial is testingMetronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast CancerWho this might be right forMetastatic Breast Cancer Johannes Gutenberg University Mainz 9
Testing effectiveness (Phase 2)Looking for participantsNCT05768139What this trial is testingFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsWho this might be right forBreast CancerSolid Tumors, Adult Eli Lilly and Company 880
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339281What this trial is testingClinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Li Huiping 68
Not applicableLooking for participantsNCT07546695What this trial is testingRole of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC StudyWho this might be right forBreast Cancer University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Study completedNCT05963984What this trial is testingSamuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsWho this might be right forMetastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Carrick Therapeutics Limited 60
Testing effectiveness (Phase 2)Looking for participantsNCT07285382What this trial is testingDifferent Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast CancerWho this might be right forHR Positive HER2 Negative Advanced Breast Cancer wanghaibo 120
Not applicableStudy completedNCT06705504What this trial is testingA Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibWho this might be right forHormone Receptor Positive HER-2 Negative Breast Cancer Novartis 435
Not applicableStudy completedNCT05709158What this trial is testingLearn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)Who this might be right forBreast Cancer Pfizer 4,184
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159What this trial is testingDalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsWho this might be right forEarly Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer Fujian Cancer Hospital 200